Wednesday, February 13, 2019 2:19:08 PM
CLSD RALLYYYYYYYYYYY and still trading massive below cash
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 10 BAGGER GEM...UNDISCOVERED low float Stock.GL
"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."
http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
